Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07573462 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
A Phase 3 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,400
- Enrollment target
NCT07573462: Recruiting Phase 3 study, sponsored by Pfizer.
NCT07573462 is a Phase 3 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 2,400 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (211% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07573462, a Phase 3 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,400 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups. This study is seeking participants who are: \- infants who are about 2 months of age About 2400 infants will be assigned by chance to one of the two groups to receive either PG4 (new vaccine) or 20vPnC (currently in use) into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Infants will take part in this study for about 16 to 19 months (about 1 and a half years). During this time, infants will have 6 study clinic visits and 1 phone call. At these study clinic visits, parent(s)/legal guardian(s) will be asked if the infant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine.
Primary Outcome
Prompted local reactions after each dose
Interventions
- BIOLOGICAL PG4
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,400 participants |
| Start Date | 2026-05-04 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 3 |
What NCT07573462 shows while recruiting
NCT07573462 is an interventional study that assigns participants to a tested intervention. Its 2,400 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (211% higher).
The record links to 0 conditions, and to 2 interventions - of which PG4 is the first listed.
NCT07573462 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07573462 about?
NCT07573462 is a clinical study titled "A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants". The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumoco...
What is the current status of trial NCT07573462?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,400 participants. The study started on 2026-05-04. Estimated completion is 2028-12-30.
What interventions are being tested in trial NCT07573462?
The interventions under investigation include: PG4 (BIOLOGICAL), 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07573462?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07573462's enrollment target sits among peer trials
2,400 89th of 2000 higher than 1,910 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
- NCT05833360 · 2,400 participants
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI